DOYLESTOWN, Pa., July 10 /PRNewswire-FirstCall/ -- The Quigley Corporation, (Nasdaq: QGLY), www.quigleyco.com, today announced that Dr. Richard Rosenbloom has resumed providing services to the Company's Quigley Pharma subsidiary. Dr. Rosenbloom had been temporarily suspended from the Company in late May, 2009.
Ted Karkus, Chairman and interim CEO of the Company, said, "We are pleased to have Dr. Rosenbloom again serving our Pharma subsidiary and helping in the development and evaluation of our new products. The Company has long acknowledged Dr. Rosenbloom's importance to the continued development of our Pharma product lines. The Company is continuing to look into the issues that resulted in Dr. Rosenbloom's prior suspension, and we are pleased to have this very talented and experienced individual back in his laboratory while these matters are under review."
Dr. Richard Rosenbloom joined the Company in 2000 as Executive Medical Director and Chairman of its Medical Advisory Board. In 2001, he helped establish Quigley Pharma with the goal of developing naturally derived compounds and botanical prescription drugs addressing therapeutic areas that have not been successfully covered by major pharmaceutical companies.
Dr. Rosenbloom has served as Director of Medical Affairs for Asta Medica Pharmaceuticals, directing international clinical drug trials in diabetes complications, pain and cancer, and as Medical Director of Biotrax Clinical Research, a contract research organization (CRO) in diabetes complications and rheumatoid arthritis.
About The Quigley Corporation
The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has several wholly owned subsidiaries; Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD-EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities. Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.
Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.
CONTACT: Ted Karkus Media Investor Relations Chairman of the Board, CEO Karen Pineman Carl Hymans The Quigley Corporation G.S. Schwartz & Co. G.S. Schwartz & Co. 215.345.0919 212.725.4500 212.725.4500 firstname.lastname@example.org email@example.com
|SOURCE The Quigley Corporation|
Copyright©2009 PR Newswire.
All rights reserved